nvjyqj3r

Property	Value
?:abstract	BACKGROUND: As of June 15, 2020, a cumulative total of 7,823,289 confirmed cases of COVID-19 have been reported across 216 countries and territories worldwide. However, there is little information on the clinical characteristics and outcomes of critically ill patients with severe COVID-19 who were admitted to intensive care units (ICUs) in Latin America. The present study evaluated the clinical characteristics and outcomes of critically ill patients with severe COVID-19 who were admitted to ICUs in Mexico. METHODS: This was a multicenter observational study that included 164 critically ill patients with laboratory-confirmed COVID-19 who were admitted to 10 ICUs in Mexico, from April 1 to April 30, 2020. Demographic data, comorbid conditions, clinical presentation, treatment, and outcomes were collected and analyzed. The date of final follow-up was June 4, 2020. RESULTS: A total of 164 patients with severe COVID-19 were included in this study. The mean age of patients was 57.3 years (SD 13.7), 114 (69.5%) were men, and 6.0% were healthcare workers. Comorbid conditions were common in patients with critical COVID-19: 38.4% of patients had hypertension and 32.3% had diabetes. Compared to survivors, nonsurvivors were older and more likely to have diabetes, hypertension or other conditions. Patients presented to the hospital a median of 7 days (IQR 4.5-9) after symptom onset. The most common presenting symptoms were shortness of breath, fever, dry cough, and myalgias. One hundred percent of patients received invasive mechanical ventilation for a median time of 11 days (IQR 6-14). A total of 139 of 164 patients (89.4%) received vasopressors, and 24 patients (14.6%) received renal replacement therapy during hospitalization. Eighty-five (51.8%) patients died at or before 30 days, with a median survival of 25 days. Age (OR, 1.05; 95% CI, 1.02-1.08; p<0.001) and C-reactive protein levels upon ICU admission (1.008; 95% CI, 1.003-1.012; p<0.001) were associated with a higher risk of in-hospital death. ICU length of stay was associated with reduced in-hospital mortality risk (OR, 0.89; 95% CI, 0.84-0.94; p<0.001). CONCLUSIONS: This observational study of critically ill patients with laboratory-confirmed COVID-19 who were admitted to the ICU in Mexico demonstrated that age and C-reactive protein level upon ICU admission were associated with in-hospital mortality, and the overall hospital mortality rate was high. TRIAL REGISTRATION: ClinicalTrials.gov, NCT04336345.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/nvjyqj3r_hasAnnotation_C0013404> <https://research.tib.eu/covid-19/entity/nvjyqj3r_hasAnnotation_C0015967> <https://research.tib.eu/covid-19/entity/nvjyqj3r_hasAnnotation_C0042397> <https://research.tib.eu/covid-19/entity/nvjyqj3r_hasAnnotation_C0231528> <https://research.tib.eu/covid-19/entity/nvjyqj3r_hasAnnotation_C0850149> <https://research.tib.eu/covid-19/entity/nvjyqj3r_hasAnnotation_C1457887>
?:creator	<https://research.tib.eu/covid-19/entity/%C3%91amendys-Silva%2C_Silvio_A%3B_Alvarado-%C3%81vila%2C_Pedro_E%3B_Dom%C3%ADnguez-Cherit%2C_Guillermo%3B_Rivero-Sigarroa%2C_Eduardo%3B_S%C3%A1nchez-Hurtado%2C_Luis_A%3B_Guti%C3%A9rrez-Villase%C3%B1or%2C_Alan%3B_Romero-Gonz%C3%A1lez%2C_Juan_P%3B_Rodr%C3%ADguez-Bautista%2C_Heber%3B_Garc%C3%ADa-Briones%2C_Alondra%3B_Garnica-Camacho%2C_C%C3%A9sar_E%3B_Cruz-Ruiz%2C_N%C3%A9stor_G%3B_Gonz%C3%A1lez-Herrera%2C_Mar%C3%ADa_O%3B_Garc%C3%ADa-Guill%C3%A9n%2C_Francisco_J%3B_Guerrero-Guti%C3%A9rrez%2C_Manuel_A%3B_Salmer%C3%B3n-Gonz%C3%A1lez%2C_Jos%C3%A9_D%3B_Romero-Guti%C3%A9rrez%2C_Laura%3B_Canto-Castro%2C_Jos%C3%A9_L%3B_Cervantes%2C_Victor_H>
?:journal	Heart_Lung
?:license	unk
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
?:source	WHO
?:title	Outcomes of patients with COVID-19 in the intensive care unit in Mexico: A multicenter observational study
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:who_covidence_id	#885289
?:year	2021

Property

Value

?:abstract

BACKGROUND: As of June 15, 2020, a cumulative total of 7,823,289 confirmed cases of COVID-19 have been reported across 216 countries and territories worldwide. However, there is little information on the clinical characteristics and outcomes of critically ill patients with severe COVID-19 who were admitted to intensive care units (ICUs) in Latin America. The present study evaluated the clinical characteristics and outcomes of critically ill patients with severe COVID-19 who were admitted to ICUs in Mexico. METHODS: This was a multicenter observational study that included 164 critically ill patients with laboratory-confirmed COVID-19 who were admitted to 10 ICUs in Mexico, from April 1 to April 30, 2020. Demographic data, comorbid conditions, clinical presentation, treatment, and outcomes were collected and analyzed. The date of final follow-up was June 4, 2020. RESULTS: A total of 164 patients with severe COVID-19 were included in this study. The mean age of patients was 57.3 years (SD 13.7), 114 (69.5%) were men, and 6.0% were healthcare workers. Comorbid conditions were common in patients with critical COVID-19: 38.4% of patients had hypertension and 32.3% had diabetes. Compared to survivors, nonsurvivors were older and more likely to have diabetes, hypertension or other conditions. Patients presented to the hospital a median of 7 days (IQR 4.5-9) after symptom onset. The most common presenting symptoms were shortness of breath, fever, dry cough, and myalgias. One hundred percent of patients received invasive mechanical ventilation for a median time of 11 days (IQR 6-14). A total of 139 of 164 patients (89.4%) received vasopressors, and 24 patients (14.6%) received renal replacement therapy during hospitalization. Eighty-five (51.8%) patients died at or before 30 days, with a median survival of 25 days. Age (OR, 1.05; 95% CI, 1.02-1.08; p<0.001) and C-reactive protein levels upon ICU admission (1.008; 95% CI, 1.003-1.012; p<0.001) were associated with a higher risk of in-hospital death. ICU length of stay was associated with reduced in-hospital mortality risk (OR, 0.89; 95% CI, 0.84-0.94; p<0.001). CONCLUSIONS: This observational study of critically ill patients with laboratory-confirmed COVID-19 who were admitted to the ICU in Mexico demonstrated that age and C-reactive protein level upon ICU admission were associated with in-hospital mortality, and the overall hospital mortality rate was high. TRIAL REGISTRATION: ClinicalTrials.gov, NCT04336345.

is ?:annotates of